Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Position Boosted by Advisors Asset Management Inc.

Advisors Asset Management Inc. boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) by 24.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,677 shares of the company’s stock after buying an additional 930 shares during the period. Advisors Asset Management Inc.’s holdings in Intellia Therapeutics were worth $242,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NTLA. Prospera Financial Services Inc bought a new position in Intellia Therapeutics in the 1st quarter valued at about $32,000. Herold Advisors Inc. bought a new position in shares of Intellia Therapeutics during the 1st quarter valued at about $62,000. Penserra Capital Management LLC bought a new position in shares of Intellia Therapeutics during the 1st quarter valued at about $97,000. Steward Partners Investment Advisory LLC boosted its position in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company’s stock valued at $123,000 after purchasing an additional 220 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of Intellia Therapeutics during the 1st quarter valued at about $165,000. Institutional investors own 88.18% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. JMP Securities raised their price objective on shares of Intellia Therapeutics from $106.00 to $111.00 and gave the company a “market outperform” rating in a research report on Monday, September 19th. Raymond James reduced their price objective on shares of Intellia Therapeutics from $127.00 to $124.00 and set an “outperform” rating for the company in a research report on Friday, November 4th. SVB Leerink raised their price objective on shares of Intellia Therapeutics from $152.00 to $158.00 and gave the company an “outperform” rating in a research report on Monday, September 19th. Citigroup assumed coverage on shares of Intellia Therapeutics in a research report on Thursday, September 1st. They set a “sell” rating and a $50.00 price objective for the company. Finally, Credit Suisse Group raised their price objective on shares of Intellia Therapeutics from $101.00 to $109.00 and gave the company an “outperform” rating in a research report on Friday, November 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $110.72.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $48.78 on Monday. The company has a 50 day simple moving average of $55.17 and a 200-day simple moving average of $55.14. The firm has a market capitalization of $3.84 billion, a price-to-earnings ratio of -8.31 and a beta of 1.83. Intellia Therapeutics, Inc. has a 52-week low of $37.08 and a 52-week high of $134.90.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.18). Intellia Therapeutics had a negative return on equity of 47.79% and a negative net margin of 859.92%. The company had revenue of $13.27 million during the quarter, compared to analysts’ expectations of $13.60 million. On average, analysts predict that Intellia Therapeutics, Inc. will post -6.08 EPS for the current year.

Intellia Therapeutics Company Profile

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Recommended Stories

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.